Affinity Asset Advisors’s BioAtla BCAB Stock Holding History

Affinity Asset Advisors’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,600	Closed	-$306K	–	88
2023 Q3	$306K	Sell	3,600 -2,900	-45%	-$370K	0.09%	76
2023 Q2	$975K	Hold	6,500	–	–	0.34%	52
2023 Q1	$871K	Buy	6,500 +3,500	+117%	+$630K	0.29%	58
2022 Q4	$1.24M	Buy	+3,000	New	+$1.24M	0.49%	49

Other funds holding BCAB

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Affinity Asset Advisors's BCAB Position: Q4 2023 in Review

Affinity Asset Advisors sold out of BioAtla (BCAB) in Q4 2023, closing a stake of 3,600 shares — an estimated $306K sold.

Affinity Asset Advisors first reported a position in BCAB in Q4 2022 and held it in 4 quarters. The position peaked at $1.24M in Q4 2022. 79 funds tracked by Wall St. Rank hold BCAB as of Q4 2023.

Affinity Asset Advisors reported no remaining BioAtla position as of Q4 2023 after selling out during the quarter.
Affinity Asset Advisors sold 3,600 BioAtla shares in Q4 2023, an estimated $306K.
Affinity Asset Advisors first reported a position in BioAtla in Q4 2022 and held it in 4 quarters.
Affinity Asset Advisors's BioAtla position peaked at $1.24M in Q4 2022.
79 funds tracked by Wall St. Rank held BioAtla as of Q4 2023.

Based on Affinity Asset Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.